You are here: Home » Companies » News
Business Standard

Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market

Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE

Press Trust of India  |  New Delhi 

medicine, drug, antibiotic, doctor, pharmaceuticals

Dr Reddy's Laboratories Tuesday said it has launched delayed-release tablets, used to treat frequent heartburn, in the US market.

"Dr Reddy's Laboratories has launched delayed-release tablets in the strength of 20 mg, an over-the-counter (OTC) store-brand equivalent of tablets, in the US," the company said in a BSE filing.

Milan Kalawadia, Dr Reddy's Laboratories and Head, US OTC and Speciality Rx businesses said, this launch illustrates the company's continued commitment to the OTC business as well as the depth and breadth of its OTC portfolio.

Quoting IRI data, Dr Reddy's Laboratories said the combined market of OTC and private label OTC products had US of around USD 492 million for the most recent twelve months ending in October 2018.

Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE.

First Published: Tue, December 11 2018. 11:05 IST
RECOMMENDED FOR YOU